Prospective Trial of a Pediatric Ventricular Assist Device

Texas Children's Hospital and Baylor College of Medicine, Houston, Texas 77030, USA. .
New England Journal of Medicine (Impact Factor: 54.42). 08/2012; 367(6):532-41. DOI: 10.1056/NEJMoa1014164
Source: PubMed

ABSTRACT Options for mechanical circulatory support as a bridge to heart transplantation in children with severe heart failure are limited.
We conducted a prospective, single-group trial of a ventricular assist device designed specifically for children as a bridge to heart transplantation. Patients 16 years of age or younger were divided into two cohorts according to body-surface area (cohort 1, <0.7 m(2); cohort 2, 0.7 to <1.5 m(2)), with 24 patients in each group. Survival in the two cohorts receiving mechanical support (with data censored at the time of transplantation or weaning from the device owing to recovery) was compared with survival in two propensity-score-matched historical control groups (one for each cohort) undergoing extracorporeal membrane oxygenation (ECMO).
For participants in cohort 1, the median survival time had not been reached at 174 days, whereas in the matched ECMO group, the median survival was 13 days (P<0.001 by the log-rank test). For participants in cohort 2 and the matched ECMO group, the median survival was 144 days and 10 days, respectively (P<0.001 by the log-rank test). Serious adverse events in cohort 1 and cohort 2 included major bleeding (in 42% and 50% of patients, respectively), infection (in 63% and 50%), and stroke (in 29% and 29%).
Our trial showed that survival rates were significantly higher with the ventricular assist device than with ECMO. Serious adverse events, including infection, stroke, and bleeding, occurred in a majority of study participants. (Funded by Berlin Heart and the Food and Drug Administration Office of Orphan Product Development; number, NCT00583661.).

Download full-text


Available from: Patricia Massicotte, Jan 15, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ventricular assist devices (VADs) are increasingly being used in pediatric patients to support cardiac failure. As more centers adopt this technology, there may be a need to transport these patients over long distances to facilitate patient care and organ transplantation. Food and Drug Administration indications for use state only that the patient must be a candidate for transplantation and does not place restrictions on the transplant capabilities of the implanting medical center. Nontransplanting institutions are able to use this technology with a predetermined agreement to transfer the patient to a partnering transplant center. We report the first two cases of interhospital air and ground transport of nonambulatory or intubated pediatric (<13 kg) patients supported by Berlin Heart EXCOR pediatric VADs and Ikus stationary drivers. We present our protocol for transporting this delicate patient population. In addition, we discuss important challenges encountered on these operations regarding vehicle transfers and the management of vehicle power supply. These two cases demonstrate that the transportation of pediatric patients on Berlin Heart VADs is feasible and safe and should be considered a treatment option in certain situations.
    ASAIO journal (American Society for Artificial Internal Organs: 1992) 01/2013; 59(5):537-541. DOI:10.1097/MAT.0b013e31829e66d7 · 1.39 Impact Factor
  • New England Journal of Medicine 08/2012; 367(6):567-8. DOI:10.1056/NEJMe1206893 · 54.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To the Editor: The selection of controls in observational studies is challenging. The propensity-score methods use baseline variables as predictors and group assignment as the outcome.(1) The resulting model is applied to identify controls whose probability of receiving the intervention is close to that of patients who do receive the intervention. In theory, this approach allows apple-to-apple comparison of groups.(1) This goal is not adequately accomplished in the analysis by Fraser et al. (Aug. 9 issue).(2) The authors compared outcomes in U.S. children receiving mechanical circulatory support from a ventricular assist device (Berlin Heart) with outcomes reported for a registry-based . . .
    New England Journal of Medicine 11/2012; 367(22):2159-61. DOI:10.1056/NEJMc1212304#SA2 · 54.42 Impact Factor